Archive · 24 Jul 2025
Lupin Receives USFDA Approval for Diabetes Medications
Imagine you have a medicine company named Lupin.
They just got permission from the US government to sell some new medicines.
These medicines help people with diabetes.
One medicine helps adults and kids with type 2 diabetes control their blood sugar.
The other is used in emergencies when people with diabetes have very low blood sugar.
Lupin will make these medicines in India.
This will help more people get the medicine they need.
Lupin received USFDA approval for generic diabetes medications.
Approvals cover Liraglutide Injection and glucagon for injection vials.
Liraglutide Injection is bioequivalent to Victoza Injection, used for type 2 diabetes.
Glucagon for Injection is bioequivalent to Eli Lilly's product, treats severe hypoglycemia.
The products will be manufactured at Lupin's Nagpur facility.
- Who
- Lupin, a pharmaceutical company, received approval from the USFDA.
- What
- Lupin received USFDA approval for generic diabetes medications.
- When
- The news was published on July 24, 2025.
- Where
- The products will be manufactured in Nagpur, India.
- Why
- To expand access to critical therapies for patients.
- Company
- Lupin
- Approval Agency
- USFDA
- Approved Drugs
- Liraglutide Injection, Glucagon for Injection
- Liraglutide Target
- Type 2 Diabetes
- Glucagon Target
- Severe Hypoglycemia
- Liraglutide Sales (US)
- $458 million (estimated annual)
- Glucagon Sales (US)
- $124 million (estimated annual)
- Location
- Nagpur, India